[go: up one dir, main page]

ZA200703394B - Combination approaches for generating immune responses - Google Patents

Combination approaches for generating immune responses

Info

Publication number
ZA200703394B
ZA200703394B ZA200703394A ZA200703394A ZA200703394B ZA 200703394 B ZA200703394 B ZA 200703394B ZA 200703394 A ZA200703394 A ZA 200703394A ZA 200703394 A ZA200703394 A ZA 200703394A ZA 200703394 B ZA200703394 B ZA 200703394B
Authority
ZA
South Africa
Prior art keywords
immune responses
generating immune
combination approaches
approaches
combination
Prior art date
Application number
ZA200703394A
Other languages
English (en)
Inventor
Susan W Barnet
Gomez-Roman Victor Raul
Robert-Guroff Marjorie
Indresh K Srivastava
Original Assignee
Novartis Vaccines & Diagnostic
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Us Gov Health & Human Serv filed Critical Novartis Vaccines & Diagnostic
Publication of ZA200703394B publication Critical patent/ZA200703394B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200703394A 2004-11-01 2007-04-25 Combination approaches for generating immune responses ZA200703394B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62450604P 2004-11-01 2004-11-01

Publications (1)

Publication Number Publication Date
ZA200703394B true ZA200703394B (en) 2008-08-27

Family

ID=36319789

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703394A ZA200703394B (en) 2004-11-01 2007-04-25 Combination approaches for generating immune responses

Country Status (6)

Country Link
US (1) US20100015211A1 (fr)
EP (2) EP1814583A2 (fr)
CN (1) CN101072585A (fr)
CA (1) CA2585672A1 (fr)
WO (1) WO2006050394A2 (fr)
ZA (1) ZA200703394B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
GB0906004D0 (en) * 2009-04-07 2009-05-20 Omnifone Ltd MusicStation desktop
KR20130081526A (ko) 2012-01-09 2013-07-17 삼성전자주식회사 저장 장치, 그것을 포함하는 전자 장치, 및 그것의 데이터 관리 방법들
US8751963B1 (en) 2013-01-23 2014-06-10 Splunk Inc. Real time indication of previously extracted data fields for regular expressions
US9594814B2 (en) 2012-09-07 2017-03-14 Splunk Inc. Advanced field extractor with modification of an extracted field
US10394946B2 (en) 2012-09-07 2019-08-27 Splunk Inc. Refining extraction rules based on selected text within events
US8751499B1 (en) 2013-01-22 2014-06-10 Splunk Inc. Variable representative sampling under resource constraints
US9753909B2 (en) 2012-09-07 2017-09-05 Splunk, Inc. Advanced field extractor with multiple positive examples
US20140208217A1 (en) 2013-01-22 2014-07-24 Splunk Inc. Interface for managing splittable timestamps across event records
US8682906B1 (en) 2013-01-23 2014-03-25 Splunk Inc. Real time display of data field values based on manual editing of regular expressions
US9152929B2 (en) 2013-01-23 2015-10-06 Splunk Inc. Real time display of statistics and values for selected regular expressions
AP2017009846A0 (en) * 2014-09-26 2017-03-31 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
CN112770770A (zh) * 2018-09-25 2021-05-07 扬森疫苗与预防公司 共定位施用疫苗组分诱导针对人类免疫缺陷病毒的免疫应答的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82592A (en) 1868-09-29 Improvement in potato-digger
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0091539B2 (fr) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (fr) 1983-12-23 1986-01-02 Monash University PRODUCTION D'INTERFERON $g(a) HUMAIN
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4879227A (en) 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
EP0434713B1 (fr) 1988-09-13 1994-10-12 Chiron Corporation Muteines d'enveloppe du vih-1 depourvues de domaines hypervariables
WO1990006370A1 (fr) 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Interleucine-6 synthetique
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
DE69131513T3 (de) 1990-03-21 2005-05-25 Geneart Gmbh Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon
WO1992001800A1 (fr) 1990-07-20 1992-02-06 Chiron Corporation Procede de transformation integrante de levure au moyen d'elements repetitifs disperses
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
EP0608261B1 (fr) 1991-09-13 2002-11-27 Chiron Corporation Compositions immunoreactives de polypeptide du virus de l'hepatite c
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2141188A1 (fr) 1992-07-27 1994-02-03 Manlio G. Abele Aimants a forte puissance pour applications medicales
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
JPH08511007A (ja) * 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
JPH10512242A (ja) 1994-12-30 1998-11-24 カイロン コーポレイション 組み合わせ遺伝子送達ビヒクル
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1997038087A2 (fr) 1996-04-05 1997-10-16 Chiron Corporation Vecteurs a base d'alphavirus de recombinaison, presentant une inhibition reduite de la synthese macromoleculaire cellulaire
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
DK1100468T3 (da) 1998-07-29 2006-07-31 Chiron Corp Mikropartikler med adsorbent-overflader, fremgangsmåder til fremstilling af disse samt anvendelser deraf
EP2206785A1 (fr) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
CA2358915C (fr) 1998-12-31 2010-06-01 Chiron Corporation Polypeptides vih env modifies
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2001081609A2 (fr) * 2000-03-22 2001-11-01 Chiron Corporation Compositions et procedes conçus pour generer une reponse immune par des systemes de vecteurs a base d'alphavirus
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002003917A2 (fr) * 2000-07-07 2002-01-17 Alphavax, Inc. Vecteurs d'alphavirus et virosomes avec genes de vih modifies, a utiliser comme vaccins
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
WO2003004620A2 (fr) * 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
CA2452119C (fr) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
CA2458995C (fr) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20050106123A1 (en) * 2002-03-13 2005-05-19 Emini Emilio A. Method of inducing an enhanced immune response against hiv
CA2478651A1 (fr) * 2002-03-13 2003-09-25 Merck & Co., Inc. Procede visant a induire une reponse immunitaire renforcee contre le vih

Also Published As

Publication number Publication date
CA2585672A1 (fr) 2006-05-11
WO2006050394A3 (fr) 2006-08-24
EP2266602A2 (fr) 2010-12-29
EP2266602A3 (fr) 2011-08-10
US20100015211A1 (en) 2010-01-21
WO2006050394A2 (fr) 2006-05-11
CN101072585A (zh) 2007-11-14
EP1814583A2 (fr) 2007-08-08

Similar Documents

Publication Publication Date Title
ZA200703394B (en) Combination approaches for generating immune responses
GB2411766B (en) Thermoelectric generator
EP1880726A4 (fr) Agents modulant la fonction immune
GB0411411D0 (en) Vaccines
EP1806072A4 (fr) Dispositif d'inclinaison
ZAA200500516S (en) Chairs
AU302836S (en) Chair
ZAA200500260S (en) Chairs
DE602005013289D1 (en) Generator
ZA200407318B (en) Barbecue arrangement
GB0405351D0 (en) Cubicle
HU0600283V0 (en) Cushion
GB0415805D0 (en) Chair
AP2709A (en) An anti-theileriosis vaccine
GB0428188D0 (en) Seating apparatus
PL366681A1 (en) Generating set
AU157125S (en) An armchair
GB0421945D0 (en) Seating apparatus
GB2414491B (en) Coving
GB0410489D0 (en) Seating device
GB0427044D0 (en) Seating device
GB0416658D0 (en) Rotocyclone generator
GB0404102D0 (en) Immune modulator
GB0425684D0 (en) Autoclave
AU302760S (en) Chair